{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725590",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725590_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  aceclofenac  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725591",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725591_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">Acenocoumarol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acenocoumarol   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725592",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725592_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"afatinib\" outputclass=\"int-drug\">afatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  afatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Afatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725593",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725593_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"aflibercept\" outputclass=\"int-drug\">aflibercept</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  aflibercept  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aflibercept</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725594",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725594_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"alemtuzumab\" outputclass=\"int-drug\">alemtuzumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  alemtuzumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alemtuzumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725595",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725595_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alteplase\" outputclass=\"int-drug\">Alteplase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alteplase   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725596",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725596_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">Amiodarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Amiodarone   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725597",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725597_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"amsacrine\" outputclass=\"int-drug\">amsacrine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  amsacrine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amsacrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725598",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725598_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  anagrelide  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725599",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725599_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"anakinra\" outputclass=\"int-drug\">anakinra</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  anakinra  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anakinra</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725600",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725600_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apixaban\" outputclass=\"int-drug\">Apixaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apixaban   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725601",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725601_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aprepitant\" outputclass=\"int-drug\">Aprepitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aprepitant   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aprepitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725602",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725602_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"argatroban\" outputclass=\"int-drug\">Argatroban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Argatroban   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Argatroban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725603",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725603_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  arsenic trioxide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725604",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725604_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"asparaginase\" outputclass=\"int-drug\">asparaginase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  asparaginase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asparaginase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725605",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725605_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  aspirin  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725606",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725606_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725607",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725607_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  axitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725608",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725608_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"azacitidine\" outputclass=\"int-drug\">azacitidine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  azacitidine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azacitidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725609",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725609_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"azathioprine\" outputclass=\"int-drug\">azathioprine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  azathioprine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azathioprine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725610",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725610_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"balsalazide\" outputclass=\"int-drug\">balsalazide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  balsalazide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Balsalazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725611",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725611_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"belimumab\" outputclass=\"int-drug\">belimumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  belimumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Belimumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725612",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725612_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"bendamustine\" outputclass=\"int-drug\">bendamustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  bendamustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendamustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725613",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725613_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  bevacizumab  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725613_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  ibrutinib  and  bevacizumab  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725614",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725614_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bivalirudin\" outputclass=\"int-drug\">Bivalirudin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bivalirudin   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bivalirudin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725615",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725615_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"bleomycin\" outputclass=\"int-drug\">bleomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  bleomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bleomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725616",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725616_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"blinatumomab\" outputclass=\"int-drug\">blinatumomab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  blinatumomab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Blinatumomab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725617",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725617_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  bortezomib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bortezomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725618",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725618_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  bosutinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725619",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725619_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-drug\">brentuximab vedotin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  brentuximab vedotin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brentuximab vedotin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725620",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725620_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"busulfan\" outputclass=\"int-drug\">busulfan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  busulfan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Busulfan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725621",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725621_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">cabazitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  cabazitaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabazitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725622",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725622_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  cabozantinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725623",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725623_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"canakinumab\" outputclass=\"int-drug\">canakinumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  canakinumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canakinumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725624",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725624_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"cangrelor\" outputclass=\"int-drug\">cangrelor</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  cangrelor  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cangrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725625",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725625_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"capecitabine\" outputclass=\"int-drug\">capecitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  capecitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capecitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725626",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725626_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the exposure to   ibrutinib .  Manufacturer advises avoid or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725627",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725627_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"carbimazole\" outputclass=\"int-drug\">carbimazole</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  carbimazole  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbimazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725628",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725628_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  carboplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725629",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725629_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"carfilzomib\" outputclass=\"int-drug\">carfilzomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  carfilzomib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carfilzomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725630",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725630_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"carmustine\" outputclass=\"int-drug\">carmustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  carmustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carmustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725631",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725631_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  celecoxib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725632",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725632_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ceritinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725633",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725633_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"cetuximab\" outputclass=\"int-drug\">cetuximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  cetuximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cetuximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725634",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725634_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"chlorambucil\" outputclass=\"int-drug\">chlorambucil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  chlorambucil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorambucil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725635",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725635_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">cilostazol</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  cilostazol  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cilostazol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725636",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725636_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ciprofloxacin\" outputclass=\"int-drug\">Ciprofloxacin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ciprofloxacin   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciprofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725637",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725637_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  cisplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725638",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725638_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  citalopram  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725639",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725639_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"cladribine\" outputclass=\"int-drug\">cladribine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  cladribine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cladribine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725640",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725640_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725641",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725641_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"clofarabine\" outputclass=\"int-drug\">clofarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  clofarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clofarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725642",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725642_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">clopidogrel</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  clopidogrel  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725643",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725643_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  clozapine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clozapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725644",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725644_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"co-trimoxazole\" outputclass=\"int-drug\">co-trimoxazole</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  co-trimoxazole  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Co-trimoxazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725645",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725645_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725646",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725646_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"crisantaspase\" outputclass=\"int-drug\">crisantaspase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  crisantaspase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crisantaspase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725647",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725647_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">crizotinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  crizotinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725647_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">Crizotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Crizotinib   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725648",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725648_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"cyclophosphamide\" outputclass=\"int-drug\">cyclophosphamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  cyclophosphamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclophosphamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725649",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725649_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"cytarabine\" outputclass=\"int-drug\">cytarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  cytarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cytarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725650",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725650_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">Dabigatran</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabigatran   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725651",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725651_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"dabrafenib\" outputclass=\"int-drug\">dabrafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  dabrafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabrafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725652",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725652_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"dacarbazine\" outputclass=\"int-drug\">dacarbazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  dacarbazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dacarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725653",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725653_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"dactinomycin\" outputclass=\"int-drug\">dactinomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  dactinomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dactinomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725654",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725654_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">Dalteparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dalteparin   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725655",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725655_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"danaparoid\" outputclass=\"int-drug\">Danaparoid</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Danaparoid   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Danaparoid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725656",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725656_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  dapoxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725657",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725657_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725658",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725658_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  dasatinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725658_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  ibrutinib  and  dasatinib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725659",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725659_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"daunorubicin\" outputclass=\"int-drug\">daunorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  daunorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daunorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725660",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725660_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"decitabine\" outputclass=\"int-drug\">decitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  decitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Decitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725661",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725661_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"deferiprone\" outputclass=\"int-drug\">deferiprone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  deferiprone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferiprone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725662",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725662_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"dexibuprofen\" outputclass=\"int-drug\">dexibuprofen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  dexibuprofen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725663",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725663_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  dexketoprofen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725664",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725664_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  diclofenac  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725665",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725665_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">Diltiazem</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Diltiazem   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725666",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725666_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  dipyridamole  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725667",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725667_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"docetaxel\" outputclass=\"int-drug\">docetaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  docetaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Docetaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725668",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725668_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"doxorubicin\" outputclass=\"int-drug\">doxorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  doxorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725669",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725669_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725670",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725670_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  duloxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725671",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725671_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">Edoxaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Edoxaban   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725672",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725672_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">Enoxaparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enoxaparin   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725673",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725673_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the exposure to   ibrutinib .  Manufacturer advises avoid or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725674",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725674_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"epirubicin\" outputclass=\"int-drug\">epirubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  epirubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epirubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725675",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725675_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  epoprostenol  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725676",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725676_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"eptifibatide\" outputclass=\"int-drug\">eptifibatide</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  eptifibatide  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eptifibatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725677",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725677_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  eribulin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725678",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725678_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">Erythromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Erythromycin   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725679",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725679_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  escitalopram  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725680",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725680_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"estramustine\" outputclass=\"int-drug\">estramustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  estramustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Estramustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725681",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725681_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ethosuximide\" outputclass=\"int-drug\">ethosuximide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ethosuximide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ethosuximide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725682",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725682_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  etodolac  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725683",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725683_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"etoposide\" outputclass=\"int-drug\">etoposide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  etoposide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoposide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725684",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725684_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  etoricoxib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725685",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725685_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"everolimus\" outputclass=\"int-drug\">everolimus</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  everolimus  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Everolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725686",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725686_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluconazole   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725687",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725687_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"fludarabine\" outputclass=\"int-drug\">fludarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  fludarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725688",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725688_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"fluorouracil\" outputclass=\"int-drug\">fluorouracil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  fluorouracil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluorouracil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725689",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725689_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  fluoxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725690",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725690_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  flurbiprofen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725691",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725691_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  fluvoxamine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725692",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725692_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fondaparinux\" outputclass=\"int-drug\">Fondaparinux</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fondaparinux   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fondaparinux</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725693",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725693_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725694",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725694_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fosaprepitant\" outputclass=\"int-drug\">Fosaprepitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor toxicity</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fosaprepitant   is predicted to   slightly   increase   the exposure to   ibrutinib .  Manufacturer advises monitor toxicity .    \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosaprepitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725695",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725695_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the exposure to   ibrutinib .  Manufacturer advises avoid or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725696",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725696_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725697",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725697_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"gefitinib\" outputclass=\"int-drug\">gefitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  gefitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gefitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725698",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725698_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"gemcitabine\" outputclass=\"int-drug\">gemcitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  gemcitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemcitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725699",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725699_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"grapefruit juice\" outputclass=\"int-drug\">Grapefruit juice</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Grapefruit juice   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Grapefruit juice</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725700",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725700_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"heparin (unfractionated)\" outputclass=\"int-drug\">Heparin (unfractionated)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Heparin (unfractionated)   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin (unfractionated)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725701",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725701_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"hydroxycarbamide\" outputclass=\"int-drug\">hydroxycarbamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  hydroxycarbamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxycarbamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725702",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725702_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ibuprofen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725703",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725703_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"idarubicin\" outputclass=\"int-drug\">idarubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  idarubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idarubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725704",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725704_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">idelalisib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  idelalisib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725704_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">Idelalisib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Idelalisib   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725705",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725705_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ifosfamide\" outputclass=\"int-drug\">ifosfamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ifosfamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ifosfamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725706",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725706_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  iloprost  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725707",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725707_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  imatinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725707_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"imatinib\" outputclass=\"int-drug\">Imatinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Imatinib   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725708",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725708_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  indometacin  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725709",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725709_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  inotersen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotersen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725710",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725710_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"interferon alfa\" outputclass=\"int-drug\">interferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  interferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Interferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725711",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725711_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"interferon beta\" outputclass=\"int-drug\">interferon beta</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  interferon beta  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Interferon beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725712",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725712_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"irinotecan\" outputclass=\"int-drug\">irinotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  irinotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irinotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725713",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725713_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"isavuconazole\" outputclass=\"int-drug\">Isavuconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Isavuconazole   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isavuconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725714",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725714_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725715",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725715_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725716",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725716_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ketoprofen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725717",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725717_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ketorolac  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725718",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725718_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">leflunomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  leflunomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725719",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725719_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"lenalidomide\" outputclass=\"int-drug\">lenalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  lenalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725720",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725720_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  linezolid  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linezolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725721",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725721_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"lomustine\" outputclass=\"int-drug\">lomustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  lomustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725722",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725722_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725723",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725723_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  mefenamic acid  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725724",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725724_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  meloxicam  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725725",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725725_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"melphalan\" outputclass=\"int-drug\">melphalan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  melphalan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Melphalan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725726",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725726_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"mercaptopurine\" outputclass=\"int-drug\">mercaptopurine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  mercaptopurine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mercaptopurine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725727",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725727_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  methotrexate  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725728",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725728_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"mitomycin\" outputclass=\"int-drug\">mitomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  mitomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725729",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725729_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"mitotane\" outputclass=\"int-drug\">mitotane</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  mitotane  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725729_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Mitotane   is predicted to   decrease   the exposure to   ibrutinib .  Manufacturer advises avoid or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725730",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725730_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"mitoxantrone\" outputclass=\"int-drug\">mitoxantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  mitoxantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitoxantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725731",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725731_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"mycophenolate\" outputclass=\"int-drug\">mycophenolate</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  mycophenolate  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mycophenolate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725732",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725732_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  nabumetone  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725733",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725733_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  naproxen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725734",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725734_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"nelarabine\" outputclass=\"int-drug\">nelarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  nelarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nelarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725735",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725735_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"netupitant\" outputclass=\"int-drug\">Netupitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Netupitant   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Netupitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725736",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725736_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">Nicotinic acid</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicotinic acid   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725737",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725737_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  nilotinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725737_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">Nilotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Nilotinib   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725738",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725738_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"nivolumab\" outputclass=\"int-drug\">nivolumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  nivolumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nivolumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725739",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725739_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"obinutuzumab\" outputclass=\"int-drug\">obinutuzumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  obinutuzumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Obinutuzumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725740",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725740_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ofatumumab\" outputclass=\"int-drug\">ofatumumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ofatumumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ofatumumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725741",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725741_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  olanzapine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olanzapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725742",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725742_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"olaparib\" outputclass=\"int-drug\">olaparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  olaparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725743",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725743_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"olsalazine\" outputclass=\"int-drug\">olsalazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  olsalazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olsalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725744",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725744_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"omega-3-acid ethyl esters\" outputclass=\"int-drug\">Omega-3-acid ethyl esters</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Omega-3-acid ethyl esters   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omega-3-acid ethyl esters</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725745",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725745_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  oxaliplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725746",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725746_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  paclitaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paclitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725747",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725747_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"panitumumab\" outputclass=\"int-drug\">panitumumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  panitumumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panitumumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725748",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725748_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  panobinostat  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725749",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725749_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  parecoxib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725750",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725750_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  paroxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725751",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725751_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  pazopanib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725752",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725752_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"pegaspargase\" outputclass=\"int-drug\">pegaspargase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  pegaspargase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pegaspargase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725753",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725753_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"peginterferon alfa\" outputclass=\"int-drug\">peginterferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  peginterferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Peginterferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725754",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725754_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"peginterferon beta-1a\" outputclass=\"int-drug\">peginterferon beta-1a</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  peginterferon beta-1a  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Peginterferon beta-1a</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725755",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725755_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  pemetrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725756",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725756_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  pentamidine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725757",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725757_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"pentostatin\" outputclass=\"int-drug\">pentostatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  pentostatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentostatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725758",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725758_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenindione\" outputclass=\"int-drug\">Phenindione</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenindione   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725759",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725759_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   ibrutinib .  Manufacturer advises avoid or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725760",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725760_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the exposure to   ibrutinib .  Manufacturer advises avoid or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725761",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725761_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  piroxicam  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725762",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725762_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"pixantrone\" outputclass=\"int-drug\">pixantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  pixantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pixantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725763",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725763_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"pomalidomide\" outputclass=\"int-drug\">pomalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  pomalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pomalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725764",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725764_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"posaconazole\" outputclass=\"int-drug\">Posaconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Posaconazole   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Posaconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725765",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725765_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"prasugrel\" outputclass=\"int-drug\">prasugrel</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  prasugrel  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prasugrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725766",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725766_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"primaquine\" outputclass=\"int-drug\">primaquine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  primaquine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primaquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725767",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725767_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   ibrutinib .  Manufacturer advises avoid or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725768",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725768_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"procarbazine\" outputclass=\"int-drug\">procarbazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  procarbazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Procarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725769",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725769_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"propylthiouracil\" outputclass=\"int-drug\">propylthiouracil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  propylthiouracil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propylthiouracil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725770",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725770_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"pyrimethamine\" outputclass=\"int-drug\">pyrimethamine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  pyrimethamine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pyrimethamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725771",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725771_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"raltitrexed\" outputclass=\"int-drug\">raltitrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  raltitrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Raltitrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725772",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725772_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ramucirumab\" outputclass=\"int-drug\">ramucirumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ramucirumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramucirumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725773",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725773_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  regorafenib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725773_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  ibrutinib  and  regorafenib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725774",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725774_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   ibrutinib .  Manufacturer advises avoid or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725775",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725775_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725776",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725776_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"rituximab\" outputclass=\"int-drug\">rituximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  rituximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rituximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725777",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725777_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">Rivaroxaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rivaroxaban   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725778",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725778_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ruxolitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725779",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725779_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">Saquinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Saquinavir   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saquinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725780",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725780_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  sertraline  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725781",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725781_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"siltuximab\" outputclass=\"int-drug\">siltuximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  siltuximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Siltuximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725782",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725782_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  sorafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725783",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725783_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's Wort\" outputclass=\"int-drug\">St John's Wort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "St John's Wort   is predicted to   decrease   the exposure to   ibrutinib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's Wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725784",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725784_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"streptokinase\" outputclass=\"int-drug\">Streptokinase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Streptokinase   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725785",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725785_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"sulfadiazine\" outputclass=\"int-drug\">sulfadiazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  sulfadiazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfadiazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725786",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725786_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"sulfasalazine\" outputclass=\"int-drug\">sulfasalazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  sulfasalazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "197",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfasalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725787",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725787_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"sulfinpyrazone\" outputclass=\"int-drug\">sulfinpyrazone</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  sulfinpyrazone  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "198",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfinpyrazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725788",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725788_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  sulindac  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "199",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725789",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725789_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  sunitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "200",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725790",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725790_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"temozolomide\" outputclass=\"int-drug\">temozolomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  temozolomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "201",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temozolomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725791",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725791_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"temsirolimus\" outputclass=\"int-drug\">temsirolimus</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  temsirolimus  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "202",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temsirolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725792",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725792_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenecteplase\" outputclass=\"int-drug\">Tenecteplase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenecteplase   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "203",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenecteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725793",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725793_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  tenoxicam  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "204",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725794",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725794_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  thalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "205",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725795",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725795_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"thiotepa\" outputclass=\"int-drug\">thiotepa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  thiotepa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "206",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiotepa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725796",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725796_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  tiaprofenic acid  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "207",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725797",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725797_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"ticagrelor\" outputclass=\"int-drug\">ticagrelor</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  ticagrelor  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "208",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ticagrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725798",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725798_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">Tinzaparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "209",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725799",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725799_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"tioguanine\" outputclass=\"int-drug\">tioguanine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  tioguanine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "210",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tioguanine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725800",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725800_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "211",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725801",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725801_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"tirofiban\" outputclass=\"int-drug\">tirofiban</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  tirofiban  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "212",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tirofiban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725802",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725802_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  tolfenamic acid  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "213",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725803",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725803_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"topotecan\" outputclass=\"int-drug\">topotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  topotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "214",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725804",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725804_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"trabectedin\" outputclass=\"int-drug\">trabectedin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  trabectedin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "215",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trabectedin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725805",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725805_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  trastuzumab emtansine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725805_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  ibrutinib  and  trastuzumab emtansine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "216",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725806",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725806_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"treosulfan\" outputclass=\"int-drug\">treosulfan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  treosulfan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "217",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treosulfan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725807",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725807_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"urokinase\" outputclass=\"int-drug\">Urokinase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Urokinase   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "218",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Urokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725808",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725808_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  valganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "219",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725809",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725809_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  venlafaxine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "220",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725810",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725810_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"verapamil\" outputclass=\"int-drug\">Verapamil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Verapamil   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "221",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725811",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725811_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  vinblastine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "222",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinblastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725812",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725812_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  vincristine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "223",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725813",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725813_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  vindesine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "224",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vindesine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725814",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725814_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  vinflunine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "225",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725815",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725815_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  vinorelbine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "226",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinorelbine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725816",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725816_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"vismodegib\" outputclass=\"int-drug\">vismodegib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  vismodegib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "227",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vismodegib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725817",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725817_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voriconazole   is predicted to   very markedly   increase   the exposure to   ibrutinib .  Manufacturer advises avoid potent inhibitors of CYP3A4 or adjust  ibrutinib  dose .    \n\n"
						}
					],
					"hasOrder": "228",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725818",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725818_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  vortioxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "229",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725819",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725819_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"warfarin\" outputclass=\"int-drug\">Warfarin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Warfarin   is predicted to   increase   the risk of bleeding events when given with   ibrutinib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "230",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725820",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2#bnf_i1557280725820_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ibrutinib\" outputclass=\"int-heading-drug\">ibrutinib</ph> and <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">zidovudine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ibrutinib  and  zidovudine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "231",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zidovudine</title>"
					}
				}
			],
			"hasSearchLabel": " Ibrutinib  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/ibrutinib-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Ibrutinib </title>"
			},
			"rdfs:label": "ibrutinib"
		}
	]
}